Sepsis and septic shock: Endothelial molecular pathogenesis associated with vascular microthrombotic disease

Thrombosis Journal

Volumn 17, Issue 1, 2019, Pages

  Chang, Jae C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti microthrombotic therapy; C5b 9 (membrane attack complex MAC ); Disseminated intravascular coagulation ("DIC", ill founded DIC); Disseminated intravascular microthrombosis (DIT); Endotheliopathy; Microthrombogenesis; Multiorgan dysfunction syndrome (MODS); Therapeutic plasma exchange (TPE); TTP like syndrome; Unusually large von Willebrand factor multimers (ULVWF); Vascular microthrombotic disease (VMTD)

Indexed keywords

COMPLEMENT MEMBRANE ATTACK COMPLEX; VON WILLEBRAND FACTOR;

ADRENAL INSUFFICIENCY; ANTICOAGULANT THERAPY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; COMBINED MICRO MACROTHROMBOTIC SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CRITICALLY ILL PATIENT; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR MICROTHROMBOSIS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; EXOCYTOSIS; HEMOSTASIS; HUMAN; INFLAMMATION; MICROTHROMBUS; MULTIPLE ORGAN FAILURE; NONHUMAN; ORGANOTROPISM; PATHOGENESIS; PHENOTYPE; PLASMA EXCHANGE; REVIEW; SEPSIS; SEPSIS ASSOCIATED COAGULOPATHY; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THEORY; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TROPISM; TWO ACTIVATION THEORY OF THE ENDOTHELIUM;

EID: 85066938602     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/s12959-019-0198-4     Document Type: Review

References (143)

1. Chang JC. Thrombocytopenia in critically ill patients due to vascular microthrombotic disease: pathogenesis based on "two activation theory of the endothelium". Vascul Dis Ther. 2017;2:1-7.
2. Chang JC. Disseminated intravascular coagulation (DIC): is it fact or fancy? Blood Coagul Fibrinolysis. 2018;29:330-7.
3. Chang JC. TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease. Thromb J. 2018;16:20.
4. Chang JC. Thrombogenesis and thrombotic disorders based on 'two-path unifying theory of hemostasis': philosophical, physiological and phenotypical interpretation. Blood Coagul Fibrinolysis. 2018;29:585-95.
5. Dempfle CE. Coagulopathy of sepsis. Thromb Haemost. 2004;91:213-24.
6. Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-14. JAMA. 2017;318:1241-9.
7. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765-77.
8. Peters K, Unger RE, Brunner J, Kirkpatrick CJ. Molecular basis of endothelial dysfunction in sepsis. Cardiovasc Res. 2003;60:49-57.
9. Lush CW, Kvietys PR. Microvascular dysfunction in sepsis. Microcirculation. 2000;7:83-101.
10. Ince C, Mayeux PR, Nguyen T, et al. The endothelium in sepsis. Shock. 2016;45:259-70.
11. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas. 2004;15(47):305-14.
12. van der Poll T, Levi M. Crosstalk between inflammation and coagulation: the lessons of sepsis. Curr Vasc Pharmacol. 2012;10:632-8.
13. O'Brien M. The reciprocal relationship between inflammation and coagulation. Top Companion Anim Med. 2012;27:46-52.
14. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Coagulopathy of Acute Sepsis. Semin Thromb Hemost. 2015;41:650-8.
15. Okamoto K, Tamura T, Sawatsubashi Y. Sepsis and disseminated intravascular coagulation. J Intensive Care. 2016;4:23.
16. Umemura Y, Yamakawa K, Hayakawa M, Hamasaki T, Fujimi S. Screening itself for disseminated intravascular coagulation may reduce mortality in sepsis: A nationwide multicenter registry in Japan. Thromb Res. 2018;161:60-6.
17. Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35:2191-5.
18. Østerud B, Bjørklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27:605-17.
19. Chang JC. A thought on possible pathogenesis of ebola viral hemorrhagic disease and potential treatments: could it be thrombotic thrombocytopenic purpura-like syndrome? Ther Apher Dial. 2015;20:93-8.
20. Chang JC. Hemostasis based on "two-path unifying theory" and classification of hemostatic disorders. Blood Coagul Fibrinolysis. 2018;29:573-84.
21. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol. 2008;6:132-42.
22. Kerr H, Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology. 2012;217:195-203.
23. Lehto T, Meri S. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8. J Immunol. 1993;151:4941-9.
24. Brooimans RA, Van der Ark AA, Tomita M, Van Es LA, Daha MR. CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis. Eur J Immunol. 1992;22:791-7.
25. Sugita Y, Masuho Y. CD59: its role in complement regulation and potential for therapeutic use. Immunotechnology. 1995;1:157-68.
26. Helling H, Stephan B, Pindur G. Coagulation and complement system in critically ill patients. Clin Hemorheol Microcirc. 2015;61:185-93.
27. McPhaden AR, Whaley K. The complement system in sepsis and trauma. Br Med Bull. 1985;41:281-6.
28. Cross AR, Glotz D, Mooney N. The role of the endothelium during antibody-mediated rejection: from victim to accomplice. Front Immunol. 2018;9:106.
29. Chang JC. Molecular pathogenesis of STEC-HUS caused by endothelial heterogeneity and unprotected complement activation, leading to endotheliopathy and impaired ADAMTS13 activity: based on two-activation theory of the endothelium and vascular microthrombotic disease. Nephrol Renal Dis. 2017;2:1-8.
30. Osterud B, Bjorklid E. Tissue factor in blood cells and endothelial cells. Front Biosci (Elite Ed). 2012;4:289-99.
31. Pries AR, Kuebler WM. Normal endothelium. Handb Exp Pharmacol. 2006;176(176 Pt 1):1-40.
32. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 2009;108:1447-52.
33. Vincent JL, De Backer D. Microvascular dysfunction as a cause of organ dysfunction in severe sepsis. Crit Care. 2005;9(Suppl 4):S9-12.
34. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013;39:559-66.
35. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39:517-28.
36. Ulloa L, Tracey KJ. The "cytokine profile": a code for sepsis. Trends Mol Med. 2005;11:56-63.
37. Xing K, Murthy S, Liles WC, Singh JM. Clinical utility of biomarkers of endothelial activation in sepsis - a systematic review. Crit Care. 2012;16:R7.
38. Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med. 2012;2:a006429.
39. Nolan DJ, Ginsberg M, Israely E, et al. Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. Dev Cell. 2013;26:204-19.
40. McCall LI, Siqueira-Neto JL, McKerrow JH. Location, location, location: five facts about tissue tropism and pathogenesis. PLoS Pathog. 2016;12(5):e1005519.
41. Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem. 1993;268:15484-8.
42. Zeng H, Goldsmith CS, Maines TR, et al. Tropism and infectivity of influenza virus, including highly pathogenic avian H5N1 virus, in ferret tracheal differentiated primary epithelial cell cultures. J Virol. 2013;87:2597-607.
43. Caugant DA, Maiden MC. Meningococcal carriage and disease - population biology and evolution. Vaccine. 2009;27(Suppl 2):B64-70.
44. Al-Khafaji A, Nadim MK, Kellum JA. Hepatorenal Disorders. Chest. 2015;148:550-8.
45. Hadjihambi A, Arias N, Sheikh M. Jalan Hepatic encephalopathy: a critical current review. Hepatol Int. 2018;12(Suppl 1):135-47.
46. Kalaiselvan S, Sankar S, Ramamurthy M, Ghosh AR, Nandagopal B, Sridharan G. Prediction of pan-specific b-cell epitopes from nucleocapsid protein of hantaviruses causing hantavirus cardiopulmonary syndrome. J Cell Biochem. 2017;118:2320-4.
47. Petejova N, Martinek A. Acute kidney injury following acute pancreatitis: A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157:105-13.
48. Zhang XP, Tian H. Pathogenesis of pancreatic encephalopathy in severe acute pancreatitis. Hepatobiliary Pancreat Dis Int. 2007;6:134-40.
49. Bernal Monterde V, Campillo Arregui A, Sostres Homedes C, García Gil A, Simón Marco MA, Serrano Aulló MT. Acute necrotizing pancreatitis and severe hepatic failure: description of three cases. Transplant Proc. 2008;40:3117-20.
50. Sonavane A, Baradkar V, Salunkhe P, Kumar S. Waterhouse-Friderichsen syndrome in an adult patient with meningococcal meningitis. Indian J Dermatol. 2011;56:326-8.
51. Schäfer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol. 2008;6:52-60.
52. Coenen DM, Mastenbroek TG, Cosemans JMEM. Platelet interaction with activated endothelium: mechanistic insights from microfluidics. Blood. 2017;130:2819-28.
53. Turner NA, Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS One. 2013;8:e59372.
54. Valentijn KM, van Driel LF, Mourik MJ, et al. Multigranular exocytosis of Weibel-Palade bodies in vascular endothelial cells. Blood. 2010;116:1807-16.
55. Bernardo A, Ball C, Nolasco L, Choi H, Moake JL, Dong JF. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005;3:562-70.
56. Chauhan AK, Goerge T, Schneider SW, Wagner DD. Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost. 2007;5:583-9.
57. Feng S, Eyler SJ, Zhang Y, et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood. 2013;122:1487-93.
58. Pourrat O, Coudroy R, Pierre F. ADAMTS13 deficiency in severe postpartum HELLP syndrome. Br J Haematol. 2013;163:409-10.
59. Gandhi C, Motto DG, Jensen M, Lentz SR, Chauhan AK. ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. Blood. 2012;120:5224-30.
60. Fujioka M, Hayakawa K, Mishima K, et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood. 2010;115:1650-3.
61. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res. 2004;10:201-22.
62. Chang JC, Gross HM. Utility of naproxen in the differential diagnosis of fever of undetermined origin in patients with cancer. Am J Med. 1984;76:597-603.
63. Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer. 2005;13:870-7.
64. Joyce DE, Nelson DR, Grinnell BW. Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway. Crit Care Med. 2004;32:S280-6.
65. Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015;372:1629-38.
66. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 2000;26(Suppl 1):S64-74.
67. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb Hemost. 2015;41:49-60.
68. Thachil J, Warkentin TE. How do we approach thrombocytopenia in critically ill patients? Br J Haematol. 2017;177:27-38.
69. Venkata C, Kashyap R, Farmer JC, Afessa B. Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. J Intensive Care. 2013;1:9.
70. Greco E, Lupia E, Bosco O, Vizio B, Montrucchio G. Platelets and multi-organ failure in sepsis. Int J Mol Sci. 2017;18(10):2200.
71. Nguyen TC, Carcillo JA. Bench-to-bedside review: thrombocytopenia-associated multiple organ failure - a newly appreciated syndrome in the critically ill. Crit Care. 2006;10:235.
72. Levi M, Löwenberg EC. Thrombocytopenia in critically ill patients. Semin Thromb Hemost. 2008;34:417-24.
73. Schriber JR, Freedman JJ, Brandwein JM. Thrombotic thrombocytopenic purpura associated with pneumococcal sepsis. Can J Infect Dis. 1993;4:145-7.
74. Centers for Disease Control and Prevention (CDC). Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse - Tennessee, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:1-4.
75. Wang Z, Yu Z, Su J, Cao L, Zhao X, Ruan C. Sepsis-induced disseminated intravascular coagulation with features of thrombotic thrombocytopenic purpura: a fatal fulminant syndrome. Clin Appl Thromb Hemost. 2011;17:251-3.
76. Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol. 2011;86:743-51.
77. Lopes da Silva R. Viral-associated thrombotic microangiopathies. Hematol Oncol Stem Cell Ther. 2011;4(2):51-9.
78. Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010;91:1-19.
79. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004;2004:407-23.
80. Chang JC, Shipstone A, Llenado-Lee MA. Postoperative thrombotic thrombocytopenic purpura following cardiovascular surgeries. Am J Hematol. 1996;53:11-7.
81. Naqvi TA, Baumann MA, Chang JC. Post-operative thrombotic thrombocytopenic purpura: a review. Int J Clin Pract. 2004;58:169-72.
82. Chang JC, Naqvi T. Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer. Oncologist. 2003;8:375-80.
83. Scully M. Cancer and thrombotic microangiopathy. J Oncol Pract. 2016;12:531-2.
84. Yu WL, Leung T, Soo Y, Lee J, Wong KS. Thrombotic thrombocytopenic purpura with concomitant small- and large-vessel thrombosis, atypical posterior reversible encephalopathy syndrome and cerebral microbleeds. Oxf Med Case Reports. 2015;91:179-82.
85. Ibernon M, Moreso F, Carreras L, et al. Thrombotic thrombocytopenic purpura with severe large artery branch involvement. Nephrol Dial Transplant. 2005;20:467-8.
86. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323-35.
87. Sarode R. Atypical presentations of thrombotic thrombocytopenic purpura: a review. J Clin Apher. 2009;24:47-52.
88. Nguyen TC, Liu A, Liu L, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica. 2007;92:121-4.
89. Chang JC, Kathula SK. Various clinical manifestations in patients with thrombotic microangiopathy. J Investig Med. 2002;50:201-6.
90. Warkentin TE, Pai M. Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is 'shock liver' the unrecognized provocateur of ischemic limb necrosis? J Thromb Haemost. 2016;14:231-5.
91. Chang JC, Ikhlaque N. Peripheral digit ischemic syndrome can be a manifestation of postoperative thrombotic thrombocytopenic purpura. Ther Apher Dial. 2004;8:413-8.
92. Panackel C, Thomas R, Sebastian B, Mathai SK. Recent advances in management of acute liver failure. Indian J Crit Care Med. 2015;19:27-33.
93. McDonald V, Laffan M, Benjamin S, Bevan D, Machin S, Scully MA. Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry. Br J Haematol. 2009;144:430-3.
94. Dal-Pizzol F, Tomasi CD, Ritter C. Septic encephalopathy: does inflammation drive the brain crazy? Rev Bras Psiquiatr. 2014;36:251-8.
95. Balasubramaniyam N, Kolte D, Palaniswamy C, et al. Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura. Am J Med. 2013;126:1016.e1-7.
96. Mele JA 3rd, Linder S, Capozzi A. Treatment of thromboembolic complications of fulminant meningococcal septic shock. Ann Plast Surg. 1997;38:283-90.
97. Hale AJ, LaSalvia M, Kirby JE, Kimball A, Baden R. Fatal purpura fulminans and Waterhouse-Friderichsen syndrome from fulminant Streptococcus pneumoniae sepsis in an asplenic young adult. IDCases. 2016;6:1-4.
98. Qahtani SA. Acute renal failure and severe rhabdomyolysis in a patient with resistant thrombotic thrombocytopenic purpura. Int J Gen Med. 2011;4:687-9.
99. Bejan C, Constantinescu S, Dorobǎţ G, Dorobǎţ C. Hepatorenal dysfunction in sepsis: epidemiological, clinical and laboratory aspects. Rev Med Chir Soc Med Nat Iasi. 2014;118:759-63.
100. van Dongen PW, Eskes TK, Gimbrère JS, Snel P. Maternal mortality due to the hepatorenal syndrome of pre-eclampsia. A case report. Eur J Obstet Gynecol Reprod Biol. 1979;9:299-306.
101. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131:845-54.
102. Denecke B, Bigalke B, Haap M, Overkamp D, Lehnert H, Haas CS. Hantavirus infection: a neglected diagnosis in thrombocytopenia and fever? Mayo Clin Proc. 2010;85:1016-20.
103. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801-10.
104. Annane D. Adrenal insufficiency in sepsis. Curr Pharm Des. 2008;14:1882-6.
105. den Brinker M, Joosten KF, Liem O, et al. Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab. 2005;90:5110-7.
106. Hamilton D, Harris MD, Foweraker J, Gresham GA. Waterhouse-Friderichsen syndrome as a result of non-meningococcal infection. J Clin Pathol. 2004;57:208-9.
107. Harms D, Pape GR, Bohle A. Pathological anatomy of Waterhouse-Friderichsen syndrome with special reference to disseminated intravascular coagulation. Dtsch Med. 1973;98:542-7.
108. CF WP, Troster EJ, Damiani D, Carcillo JA. Absolute and relative adrenal insufficiency in children with septic shock. Crit Care Med. 2005;33:855-9.
109. Annane D, Maxime V, Ibrahim F, Alvarez JC, Abe E, Boudou P. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med. 2006;174:1319-26.
110. Maxime V, Lesur O, Annane D. Adrenal insufficiency in septic shock. Clin Chest Med. 2009;30:17-27.
111. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med. 2003;31:141-5.
112. McKay DG. Progress in disseminated intravascular coagulation. Calif Med. 1969;111:186-98.
113. Levi M, van der Poll T. A short contemporary history of disseminated intravascular coagulation. Semin Thromb Hemost. 2014;40:874-80.
114. Ten Cate H, Hackeng TM, García de Frutos P. Coagulation factor and protease pathways in thrombosis and cardiovascular disease. Thromb Haemost. 2017;117:1265-71.
115. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26-34.
116. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2:16037.
117. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1644-55.
118. Balk RA. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? Virulence. 2014;5:20-6.
119. Ogura H, Gando S, Iba T, et al. SIRS-associated coagulopathy and organ dysfunction in critically ill patients with thrombocytopenia. Shock. 2007;28:411-7.
120. Stravitz RT, Ellerbe C, Durkalski V, Reuben A, Lisman T, Lee WM. Thrombocytopenia is associated with multi-organ system failure in patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14:613-20.
121. Camous L, Veyradier A, Darmon M, et al. Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies. Intern Emerg Med. 2014;9:267-72.
122. Reid VL, McLay J. Symmetrical peripheral gangrene and disseminated intravascular coagulation associated with pelvi-ureteric junction obstruction. BMJ Case Rep. 2013;2013:bcr2012006519.
123. Ruffin N, Vasa CV, Breakstone S, Axman W. Symmetrical peripheral gangrene of bilateral feet and unilateral hand after administration of vasopressors during septic shock. BMJ Case Rep. 2018;2018:bcr-2017-223602.
124. Molos MA, Hall JC. Symmetrical peripheral gangrene and disseminated intravascular coagulation. Arch Dermatol. 1985;121:1057-61.
125. Liechti ME, Zumsteg V, Hatz CF, Herren T. Plasmodium falciparum cerebral malaria complicated by disseminated intravascular coagulation and symmetrical peripheral gangrene: case report and review. Eur J Clin Microbiol Infect Dis. 2003;22:551-4.
126. Adamski J. Thrombotic microangiopathy and indications for therapeutic plasma exchange. Hematology Am Soc Hematol Educ Program. 2014;2014:444-9.
127. Nguyen TC, Han YY. Plasma exchange therapy for thrombotic microangiopathies. Organogenesis. 2011;7:28-31.
128. Oral M, Yilmaz A, Yilmaz D, Ünal N, Tulunay M. The place of plasmapheresis in septic patients complicated with disseminated intravascular coagulation. Crit Care. 2004;8(Suppl 1):P150.
129. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med. 2002;28:1434-9.
130. Nguyen TC, Han YY, Kiss JE, Hall MW, Hassett AC, Jaffe R, Orr RA, et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med. 2008;36:2878-87.
131. Qu L, Kiss JE, Dargo G, Carcillo JA. Outcomes of previously healthy pediatric patients with fulminant sepsis-induced multisystem organ failure receiving therapeutic plasma exchange. J Clin Apher. 2011;26(4):208-13.
132. Hadem J, Hafer C, Schneider AS, Wiesner O, Beutel G, Fuehner T, et al. Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-centre study of 23 patients. BMC Anesthesiol. 2014;14:24.
133. De Simone N, Racsa L, Bevan S, Matevosyan K, Valley T, Girod C, Sarode R. Therapeutic plasma exchange in the management of sepsis and multiple organ dysfunction syndrome: a report of three cases. J Clin Apher. 2014;29:127-31.
134. Stegmayr B. Apheresis in patients with severe sepsis and multiorgan dysfunction syndrome. Transfus Apher Sci. 2008;38:203-8.
135. Rimmer E, Houston BL, Kumar A, Abou-Setta AM, Friesen C, Marshall JC, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Crit Care. 2014;18:699.
136. Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, Presneill JJ. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med. 1999;27:2096-104.
137. Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med. 2016;7:39-72.
138. Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res. 2014;3:34-45.
139. Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost. 2015;113:708-18.
140. Zheng XL. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med. 2015;66:211-25.
141. Tersteeg C, Schiviz A, De Meyer SF, Plaimauer B, Scheiflinger F, Rottensteiner H, Vanhoorelbeke K. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura. Arterioscler Thromb Vasc Biol. 2015;35:2336-42.
142. Plaimauer B, Kremer Hovinga JA, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost. 2011;9:936-44.
143. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335-46.